



# A NEW ERA IN **MASH**

## How Disease-Specific Therapies Are Changing the Game and Best Practices for Clinical Integration

# Nonalcoholic Steatohepatitis (NASH) vs Metabolic Dysfunction-Associated Steatohepatitis (MASH)

- The following presentation contains a discussion of an FDA-approved drug for the treatment of NASH
- NASH is now known as MASH to emphasize the underlying pathophysiology of this liver condition
- Presenters may use NASH and MASH interchangeably

# Faculty



**Meena Bansal, MD, FAASLD**

Professor of Medicine  
System Chief, Division of Liver Diseases  
Director, MASLD/MASH Center of Excellence  
Icahn School of Medicine at Mount Sinai  
New York, NY



**Professor Laurent Castera, MD, PhD**

Université Paris-Cité  
Department of Hepatology  
Hôpital Beaujon,  
Assistance Publique-Hôpitaux de Paris  
Centre de Recherche sur l'Inflammation Paris  
Montmartre  
Clichy, France



**Prof. Dr. med. Frank Tacke,  
MD, PhD, MHBA**

Director Medical Department of Hepatology and  
Gastroenterology,  
Charité – Universitätsmedizin Berlin,  
Campus Charité Mitte and Campus Virchow-  
Klinikum,  
Berlin, Germany

# Overview and Target Audience

**This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC.**

**This activity is supported by an educational grant from Madrigal Pharmaceuticals.**

**ACTIVITY OVERVIEW –** Mitigating disease progression due to metabolic-associated steatotic liver disease (MASLD) and metabolic-associated steatohepatitis (MASH) has been challenging due to a lack of disease-specific therapies. A new era of disease management is here with late-stage development and approval of several agents with novel mechanisms of action. This activity will explore current successes and challenges with real-world use of thyroid hormone receptor- $\beta$  (THR- $\beta$ ) agonists through case-based discussions. Updates on emerging clinical efficacy and safety data of late-stage disease-specific therapies will be examined. Also, the latest advances in noninvasive testing to assess liver disease will be presented to optimize patient screening and identification.

**TARGET AUDIENCE –** This initiative is intended for hepatology and gastroenterology healthcare providers, as well as other specialty clinicians involved in the management of patients with MASLD/MASH.

# Learning Objectives

Upon successful completion of this activity, participants should be better able to:

- **Describe** the mechanistic and clinical rationale for THR- $\beta$  agonists as a means of treating MASLD/MASH
- **Evaluate** the evidence on THR- $\beta$  agonists, and other disease-specific therapy classes, considering efficacy, safety/tolerability, and PROs
- **Identify** best practices for facilitating and documenting an accurate, non-invasive, and timely diagnosis of MASLD/MASH to support access to disease-specific therapy
- **Develop** guideline-aligned management paradigms for MASLD/MASH that incorporate pharmacotherapy tailored to individual clinical scenarios

# Agenda

- Welcome
- Screening and Diagnosis of MASLD/MASH
- Practical Aspects of MASH Treatment: Real-World Practice
- Emerging Therapies and EASL Updates
- Conclusions and Q&A

# Accreditation & Credit Designation Statements

## Criteria for Success

Certificates of completion will be awarded based on the participant's attendance and submission of the activity evaluation/claim credit form. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at [tbrignoni@akhcme.com](mailto:tbrignoni@akhcme.com).



Credit provided by AKH Inc., Advancing Knowledge in Healthcare



JOINTLY ACCREDITED PROVIDER™  
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

## Physicians

AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Type of Activity:** Application-based

**Fee Information:** There is no fee for this educational activity

# Disclosures

## Disclosure

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

**Meena Bansal, MD, FAASLD**, has disclosed the following relevant financial relationships: Advisor - Madrigal, Boston Pharma, GSK, Merck; Consultant – Novo Nordisk

**Laurent Castera, MD, PhD**, has disclosed the following relevant financial relationships: Consultant - Boehringer Ingelheim, Boston Pharmaceutical, Echosens, Gilead, GSK, Madrigal, MSD, Novo Nordisk, Pfizer, Sagimet, Siemens Healthineers; Speaker - AstraZeneca, Echosens, Gilead, Inventiva, Madrigal, and Novo Nordisk

**Prof. Dr. med. Frank Tacke, MD, PhD, MHBA**, discloses the following financial relationships: Data Safety Monitor/Advisory Board - Sanofi; Consultant - AstraZeneca, Gilead, GSK, AbbVie, BMS, Ipsen, Pfizer, Novartis, Novo Nordisk, MSD, Madrigal, Sanofi, Boehringer; Research funding - AstraZeneca, MSD, Gilead, Agomab (funding to my institution); Speaker - Honoraria Gilead, AbbVie, Falk, Merz, Sanofi, AstraZeneca, Takeda, Boehringer

## STAFF/REVIEWERS

Louis Settembrino, CHCP, Catalyst Medical Education, LLC, President and CEO: has disclosed no financial relationships.

Dorothy Caputo, MA, BSN, RN, AKH Lead Nurse Planner/Reviewer, has no financial relationships to disclose.

Trish Brignoni, AKH Director Operations & Compliance, has no financial relationships to disclose.

Stephanie S. Wenick, MPhil, Medical Writer, has served as a consultant medical writer for Nanoscope Therapeutics, Inc.

AKH and Catalyst Medical Education, LLC Planners and Reviewers, has no financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

## **Disclaimer**

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to [optout@akhcme.com](mailto:optout@akhcme.com) with your information with "Opt Out" in the subject line.

## **Disclosure of Unlabeled Use and Investigational Product**

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.